期刊文献+

艾司洛尔与毛花苷控制快速心房颤动患者心室率的短时疗效比较 被引量:2

A short-term clinical observation of intravenous esmolol and lanatoside in the treatment of rapid ventricular rate in patients with atrial fibrillation
暂未订购
导出
摘要 目的比较静脉应用艾司洛尔与毛花苷控制快速心房颤动患者心室率的短时疗效和安全性。方法60例快速心房颤动患者,心室率≥120次/min,随机分为艾司洛尔组、毛花苷组各30例。艾司洛尔组首次剂量给予0.5mg/kg,1min静注,观察5min,若心室率〉100次/min或下降〈20%,则追加0.5mg/kg,同时以0.05mg·kg-1·min-1微量泵起始维持,维持量最大可加至0.3mg·kg-1·min-1,若血压〈90/60mmHg,则停止试验。毛花苷组首次剂量给予毛花苷0.4mg或0.2mg缓慢静注,若心室率〉100次/min或下降〈20%,可追加0.2mg。观察两组用药后5min、10min、30min、60min、90min和120min心率、血压及临床表现;同时记录用药后药物起效时间及不良反应。结果两组患者用药后不同时刻的心室率均明显降低,与用药前比较差异均有统计学意义,用药2h后艾司洛尔组心室率下降幅度大于毛花苷组(P〈0.05);艾司洛尔和毛花苷组平均起效时间分别为(6.4±3.8)min和(43.1±12.6)min,两者差异具有统计学意义(P〈0.01)。艾司洛尔和毛花苷组总有效率分别为86.3%和83.3%(P〉0.05),无统计学意义;两组不良反应发生率无统计学意义。结论静脉应用艾司洛尔控制快速心房颤动患者心室率的短时疗效显著,安全性好。 Objective To evaluate the short-term efficiency of intravenous esmolol and lanatoside for the treatment of rapid ventricular rate in patients with atrial fibrillation. Methods Sixty patients with atrial fibrillation (ventricular rate ≥120 beats/minute) were randomly divided into two groups.The two groups were intravenously administered esmolol and lanatoside respectively. Heart rate and the mean response time were measured after the treatment. Adverse effects were recorded. Results Ventricular rate decreased significant in different time after treatment in two groups, but more significantly in esmolol group. The mean response time was (6.4±3.8) minutes and (43.1±12.6)minutes in esmolol and lanatoside groups respectively. No significantly changes of the total effective rate on controlling rapid atrial fibrillation were found between two groups (86.7% in esmolol group versus 83.3% in lanatoside group). Conclusion Intravenous esmolol is efficient, rapid and safe to treat rapid ventricular rate in patients with atrial fibrillation.
出处 《中国心血管病研究》 CAS 2010年第9期690-692,共3页 Chinese Journal of Cardiovascular Research
关键词 艾司洛尔 毛花苷 心房颤动 心室率 Esmolol Lanatoside Atrial fibrillation Ventricular rate
  • 相关文献

参考文献9

  • 1杜昕,马长生.心房颤动的再认识(一)[J].中国心血管病研究,2005,3(10):725-727. 被引量:33
  • 2李继敏,胡大一.慢性心房颤动心室率控制的研究现状[J].中国心血管病研究,2004,2(3):164-166. 被引量:11
  • 3Suzuki S,Nonaka A,Ahe S.Effect of esmolol on cardiovascular responses induced by scopolamine butylbromide.Masui,2005,54:1277-1281.
  • 4郭继鸿.β受体阻滞剂在心律失常治疗中的应用[J].中国心脏起搏与心电生理杂志,2007,21(1):4-6. 被引量:49
  • 5Chung MK,Shemanski L,Sherman DG,et al.Functional status in rate-versus rhythm-control strategies for atrial fibrillation:results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management(AFFIRM)Functional Status Substudy.J Am Coll Cardiol,2005,46:1891-1899.
  • 6Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation):developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Circulation,2006,114:E257-354.
  • 7戚文航.中国部分地区心房颤动住院病例回顾性调查[J].中华心血管病杂志,2003,31(12):913-916. 被引量:381
  • 8Hersi A,Wyse DG.Management of atrial fibrillation.Curr Probl Cardiol,2005,30:175-233.
  • 9卢才义,刘英明.快速心房颤动的治疗决策及效果评价[J].临床急诊杂志,2005,6(3):1-2. 被引量:3

二级参考文献30

  • 1郭继鸿.β受体阻滞剂应当成为快速心律失常治疗的基础用药[J].中国心脏起搏与心电生理杂志,2005,19(5):331-334. 被引量:79
  • 2[2]Gibbons RJJ,Antmrn EM,Alpert JS,et al. ACC/AHA /ESC guidelines for the management of patients with atrial fibrillation [J]. Eur Heart J, 2001,22: 1852 -1923
  • 3[3]Farshi R,Kistner D,Sarma JSM,et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a cross over open - label study of five drug regimens [ J ]. J Am Coll Cardiol,1999,33: 304 - 310
  • 4[5]Zoble RG, Brewington J, Olukotun AY, et al. Comparative effects of nadolol - digoxin combination therapy and digoxin monotherpy for chronic atrial fibrillation[J ]. Am J Cardiol, 1987,60: 39D- 45D
  • 5[6]Redfors A. Plasma digoxin concertration: its relation to digoxin dosage and clinical effects in patients with atrial fibrillation[ J ]. Br Heart J, 1972,34: 383 - 391
  • 6[7]Lang R, Klein HO, Weiss E, et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation[ J ]. Chest, 1983,83:491 - 499
  • 7[8]Goldman S, Probst P, Selzer A, Cohn K. Inefficacy of "therapeutic serum levels of digoxin in controlling the ventricular rate in atrial fibrillation[J]. Am J Cardiol,1975,35:651 - 655
  • 8[9]Lewis RV. Irvine N, McDevitt DG. Relationship between heart rate,exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem [ J ]. Eur Heart J,1998,9: 777 - 781
  • 9[10]Ang EL. Chan WL, Cleland JGF. et al. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation[J]. Br Heart J ,1990,64:256 - 260
  • 10[11]Sopher SM, Camm AJ. Atrial fibrillation; Maintenance of sinus rhythm versus rate control[J ]. Am J Cardiol,1996,77: 24A- 37A

共引文献465

同被引文献12

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部